These independent CME/CE activities are supported by educational grants from AbbVie Inc. and Bayer HealthCare Pharmaceuticals Inc.



Clinical Context:
Prostate Cancer
  1. Course List
Chair
faculty image
Ajjai S. Alva, MD, MBBS
  • Professor of Medicine
  • Department of Internal Medicine/Hematology-Oncology
  • University of Michigan
  • Ann Arbor, Michigan
  • Clinical Context: Prostate Cancer is designed to provide up-to-date information on current and emerging management strategies based on the most up-to-date evidence-based medicine and clinical trial results in prostate cancer. The curriculum includes case studies at the point of care and MedPage Today meeting coverage that will report on cutting-edge news as it breaks from the 111th AUA (American Urology Association) 2016 Annual Meeting, ASCO (American Society of Clinical Oncology) 2016 Annual Meeting, and ASTRO (American Society for Radiation Oncology) 2016 Annual Meeting.
  • Describe the natural history of prostate cancer, the importance of early diagnosis of this condition, and recent advances in our understanding of components of the pathophysiologic mechanisms that may serve as targets of therapy.
  • Evaluate criteria that have been developed to assess treatment response in prostate cancer and delineate how these criteria can be used to risk-stratify patients in clinical practice.
  • Formulate personalized treatment regimens that improve patient outcomes based on an understanding of the mechanism of action, efficacy and safety profiles of current and emerging treatment options.
  • Target Audience

    This series of activities is designed for oncologists, radiologists, surgeons, urologists, internists, primary care physicians, physician assistants, nurses, and pharmacists involved in the screening and treatment of patients with prostate cancer.

     

    Activity Goal

    The goal of this program is to provide information and case studies at the point of care on current and emerging management strategies based on the most up-to-date evidence-based medicine and clinical trial results in prostate cancer.